San Antonio, TX (PRWEB) September 05, 2012
Patients taking an experimental Hepatitis C drug have suffered heart failure and valve damage, prompting Bristol-Myers Squibb to unexpectedly halt all work on the drug.
“People have suffered life-changing, debilitating injuries as a result of these clinical trials.
Thomas J. Henry, Attorney
“We have already interviewed a number of injury victims from the Hepatitis C trials,” Thomas J. Henry said. “More calls are coming in and there are lawsuits already on file. People have suffered life-changing, debilitating injuries as a result of these clinical trials.”
The clinical trials were halted following the report of one death. Bristol-Myers discontinued development of BMS-986094 after reports of eight hospitalizations, the Wall Street Journal recently reported. In addition, a similar drug – IDX-184 by Idenix Pharmaceuticals – has also been placed on partial clinical hold.
Originally hailed as a possible breakthrough in Hepatitis C treatment, BMS-986094 may actually be toxic to the heart and kidneys. Hundreds of people took the drug for clinical trials before this potentially dangerous flaw was discovered. Injuries reported in trial patients include:
- Heart valve damage
- Heart attacks and heart failure
- Kidney damage
- Abnormal heart rhythms
- Fatal heart damage
Bristol is monitoring more than 100 patients who took part in the halted trial and is notifying 150 patients who were part of earlier trials, according to the Wall Street Journal. The Hepatitis C trials took place in various medical facilities across the country, including:
- New York
If you or a loved one participated in this trial and suffered damage, you are encouraged to contact an attorney immediately. Thomas J. Henry are available 24/7, night and day, at 888-956-8000 or thomasjhenrylaw.com.